XTL Biopharmaceuticals Ltd.
XTLBNASDAQHealthcareBiotechnology
Previous close
$2.78
+$0.0181 · +0.66%
XTLB company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
25
Expensive
Momentum
37
Weakening
Sentiment
48
Mixed
Risk resilience
36
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteXTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to identifying and advancing novel drug therapies for autoimmune conditions. Its primary investigational compound, hCDR1, is poised to enter Phase II trials, specifically targeting systemic lupus erythematosus and Sjogren's syndrome. The company holds a crucial licensing agreement with Yeda Research and Development Company Limited, which grants rights for the research, development, and eventual commercialization of hCDR1 across multiple therapeutic indications. Originally established in 1993 as Xenograft Technologies Ltd., the company rebranded to XTL Biopharmaceuticals Ltd. in July 1995. It operates from its headquarters in Ramat Gan, Israel.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- IL
- CEO
- Noam Band
- Listed since
- Sep 1, 2005
- Employees
- 10
Market position
52-week range
Current $2.78
- Open
- $2.78
- Previous close
- $2.7619
- Volume
- 427
- 0.01× average
- Average volume
- 84.03K
- Average daily volume
- Market cap
- 2.63M USD
- Beta
- 0.46
- Market reference 1
- 50-day average
- $2.769
- +0.40% above average
- 200-day average
- $2.9735
- -6.51% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 1.17M USD
- EV / EBITDA
- -1.55×
- Earnings yield
- -714.10%
- Free cash flow yield
- -105.03%
Profitability & efficiency
- Return on equity
- 2743.70%
- Return on assets
- -4198.19%
- Return on invested capital
- -11253.33%
Financial health
- Current ratio
- 0.4×
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | 451K USD | — | — | — |
| Cost of goods sold | — | 448K USD | — | 1K USD | 1K USD |
| Gross profit | — | 3K USD | — | −1K USD | −1K USD |
| Research and development | 28K USD | 98K USD | 31K USD | 30K USD | 30K USD |
| Selling, general, and administrative | 1.13M USD | 2.05M USD | 734K USD | 850K USD | 1M USD |
| Operating expenses | 1.69M USD | 2.18M USD | 765K USD | 880K USD | 1.03M USD |
| Interest income | 60K USD | 34K USD | 41K USD | 36K USD | 8K USD |
| Interest expense | 7K USD | 86K USD | 4K USD | 11K USD | 21K USD |
| Depreciation and amortization | — | 199K USD | 1K USD | 1K USD | 1K USD |
| Operating income | −1.69M USD | −2.17M USD | −765K USD | −880K USD | −1.03M USD |
| Net income | −6.97M USD | −1.03M USD | −1.78K USD | −1.35M USD | 435K USD |
Company facts updated Aug 24, 2026.
XTLB news
XTLB peers
Continue in GoAI
Research XTLBresearch.disclaimer